BRCC
BEARISH
$0.95
Live
BRC Inc. · NYSE
Target $2.5
(+163.2%)
$0.9
52W Range
$2.9
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$108.91M
P/E
N/A
ROE
-47.5%
Profit margin
-2.9%
Debt/Equity
0.85
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
68%
The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of 4/9, indicating borderline stability, and no available Altman Z-Score prevents a full distress risk assessment. Despite a low Price/Sales ratio of 0.28 suggesting potential undervaluation, the company is unprofitable with negative earnings, a negative ROE of -47.48%, and deteriorating profitability metrics. While recent quarterly earnings have frequently beaten extremely low expectations—sometimes by over 1000%—this reflects poor baselines rather than sustainable progress, and long-term price performance remains deeply negative with a 5-year return of -93.9%. The stock trades significantly below analyst target prices, but fundamental weaknesses, lack of profitability, and inconsistent cash flow data undermine bullish sentiment.
Key Strengths
Frequent earnings beats with an average surprise of over 300% in recent quarters, signaling possible operational improvements or aggressive cost management
Low Price/Sales ratio of 0.28 suggests potential undervaluation relative to revenue, especially compared to sector average of 11.6% revenue growth
Gross margin of 36.33% is healthy for the Packaged Foods industry, indicating pricing power or efficient production
Debt/Equity ratio of 0.85 is below sector average of 1.78, suggesting conservative leverage relative to peers
Analyst recommendation is strong_buy with a $2.50 target price, implying 163% upside from current levels
Key Risks
Piotroski F-Score of 4/9 indicates weak financial health, particularly concerning for a company with negative earnings and ROE
No Altman Z-Score available prevents proper bankruptcy risk evaluation, a critical gap for a loss-making firm
Negative profit margin (-2.86%) and ROE (-47.48%) reflect ongoing unprofitability and poor capital efficiency
Quick ratio of 0.49 indicates potential liquidity stress, as the company may struggle to meet short-term obligations without inventory sales
Extreme volatility in earnings, including a +11,341% surprise in 2022, suggests non-recurring items or accounting anomalies rather than consistent performance
AI Fair Value Estimate
Based on comprehensive analysis
$1.85
+94.7% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
31
Weak
52
41
28
33
0
AI Verdict
High-risk speculative position with unproven profitability and weak financial health, despite potential valuation upside
Key drivers: Low Piotroski score and missing Altman Z-Score suppress overall score, Negative earnings and ROE drag down health and value dimensions, High earnings surprise frequency provides minor uplift to future expectations, Analyst target implies significant upside but lacks fundamental confirmation
Confidence
70%
Value
52/100
Ref P/E, PEG, Graham Number
Positives
- Price/Sales of 0.28 is very low, suggesting possible undervaluation
- Price/Book of 2.27 is moderate despite negative earnings
Watchpoints
- No Graham Number or Intrinsic Value available due to unprofitability
- Negative earnings make P/E and PEG ratios meaningless or negative
Future
41/100
Ref Growth rates
Positives
- Revenue growth of 2.60% YoY, though low, is positive
- Recent earnings surprises suggest potential for turnaround if sustained
Watchpoints
- Forward P/E of -31.67 indicates continued expected losses
- No data on earnings growth or Q/Q trends limits visibility
Past
28/100
Ref Historical trends
Positives
- Some quarters show strong positive EPS surprises, indicating improvement from deep losses
Watchpoints
- 5-year price return of -93.9% reflects severe underperformance
- History of negative or near-zero earnings estimates being beaten from below
Health
33/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio of 1.33 shows current assets exceed liabilities
- Debt/Equity of 0.85 is below sector average
Watchpoints
- Piotroski F-Score of 4/9 indicates weak financial health
- Quick ratio of 0.49 suggests liquidity risk
- No Altman Z-Score available for distress assessment
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout history
- Dividend strength score of 0/100 confirms no income appeal
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$0.95
Analyst Target
$2.5
Upside/Downside
+163.2%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BRCC and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BRCC
BRC Inc.
Primary
|
-93.9% | -84.9% | -67.1% | -53.2% | -21.5% | -3.1% |
|
HFFG
HF Foods Group Inc.
Peer
|
-70.7% | -47.9% | -47.4% | -13.3% | +10.6% | +3.0% |
|
CHGG
Chegg, Inc.
Peer
|
-98.9% | -94.3% | +66.1% | -25.9% | +74.6% | -1.9% |
|
SKIN
The Beauty Health Company
Peer
|
-90.8% | -93.3% | +7.9% | -36.1% | -22.6% | +1.7% |
|
ISPR
Ispire Technology Inc.
Peer
|
-76.8% | -76.2% | -50.8% | -20.4% | -9.8% | +2.3% |
BRC
BRC Inc.
Primary
5Y
-93.9%
3Y
-84.9%
1Y
-67.1%
6M
-53.2%
1M
-21.5%
1W
-3.1%
HFF
HF Foods Group Inc.
Peer
5Y
-70.7%
3Y
-47.9%
1Y
-47.4%
6M
-13.3%
1M
+10.6%
1W
+3.0%
CHG
Chegg, Inc.
Peer
5Y
-98.9%
3Y
-94.3%
1Y
+66.1%
6M
-25.9%
1M
+74.6%
1W
-1.9%
SKI
The Beauty Health Company
Peer
5Y
-90.8%
3Y
-93.3%
1Y
+7.9%
6M
-36.1%
1M
-22.6%
1W
+1.7%
ISP
Ispire Technology Inc.
Peer
5Y
-76.8%
3Y
-76.2%
1Y
-50.8%
6M
-20.4%
1M
-9.8%
1W
+2.3%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-31.67
PEG Ratio
N/A
P/B Ratio
2.27
P/S Ratio
0.28
EV/Revenue
0.48
EV/EBITDA
-61.2
Market Cap
$108.91M
Profitability
Profit margins and return metrics
Profit Margin
-2.86%
Operating Margin
1.99%
Gross Margin
36.33%
ROE
-47.48%
ROA
-2.74%
Growth
Revenue and earnings growth rates
Revenue Growth
+2.6%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.85
Moderate
Current Ratio
1.33
Good
Quick Ratio
0.49
Poor
Cash/Share
$0.08
Quarterly Earnings History
EPS performance vs analyst estimates
2026-03-02
$N/A
2025-11-03
$0.04
+504.0% surprise
2025-08-04
$0.07
+341.0% surprise
2025-05-05
$0.01
+109.2% surprise
Consumer Defensive Sector Comparison
Comparing BRCC against 170 companies in the Consumer Defensive sector
(9 bullish, 60 neutral, 101 bearish)
Return on Equity (ROE)
-47.48%
This Stock
vs
-13.91%
Sector Avg
+241.2%
(Excellent)
Profit Margin
-2.86%
This Stock
vs
-7.77%
Sector Avg
-63.2%
(Weaker)
Debt to Equity
0.85
This Stock
vs
1.89
Sector Avg
-55.0%
(Less Debt)
Revenue Growth
2.6%
This Stock
vs
111.74%
Sector Avg
-97.7%
(Slower)
Current Ratio
1.33
This Stock
vs
2.29
Sector Avg
-41.7%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BRCC
BRC Inc.
|
BEARISH | $108.91M | - | -47.5% | -2.9% | $0.95 | |
|
HFFG
HF Foods Group Inc.
|
BEARISH | $110.86M | - | -17.7% | -3.2% | $2.09 | Compare |
|
CHGG
Chegg, Inc.
|
BEARISH | $115.15M | - | -66.2% | -27.4% | $1.03 | Compare |
|
SKIN
The Beauty Health Company
|
BEARISH | $116.62M | - | -16.9% | -3.2% | $0.91 | Compare |
|
ISPR
Ispire Technology Inc.
|
BEARISH | $100.26M | - | -428.6% | -36.6% | $1.75 | Compare |
BRCC
BRC Inc.
BEARISH
Mkt Cap
$109M
P/E
-
ROE
-47.5%
Price
$0.95
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-11-17 | TASLITZ STEVEN M | Director | Purchase | 100,000 | $129,430 |
| 2025-11-12 | TASLITZ STEVEN M | Director | Purchase | 100,000 | $128,450 |
| 2025-10-23 | KADENACY STEPHEN M | Director | Stock Award | 124,113 | - |
| 2025-09-15 | LANDIS MELVIN F III | Director | Stock Award | 149,264 | - |
| 2025-08-08 | TASLITZ STEVEN M | Director | Purchase | 200,000 | $284,000 |
TASLITZ STEVEN M
Director
2025-11-17
100,000 shares
·
$129,430
TASLITZ STEVEN M
Director
2025-11-12
100,000 shares
·
$128,450
KADENACY STEPHEN M
Director
2025-10-23
124,113 shares
LANDIS MELVIN F III
Director
2025-09-15
149,264 shares
TASLITZ STEVEN M
Director
2025-08-08
200,000 shares
·
$284,000
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
2 analysts
Telsey Advisory Group
2026-01-14
Outperform
Outperform
Telsey Advisory Group
2025-11-04
Outperform
Outperform
Telsey Advisory Group
2025-10-27
Outperform
Outperform
Telsey Advisory Group
2025-08-06
Outperform
Outperform
Telsey Advisory Group
2025-08-05
Outperform
Outperform
Past News Coverage
Recent headlines mentioning BRCC from our newsroom.
Newest → oldest
No matching news yet.